F&V Capital Management LLC Has $17.17 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

F&V Capital Management LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% in the first quarter, HoldingsChannel reports. The firm owned 153,240 shares of the biopharmaceutical company’s stock after selling 2,090 shares during the period. Gilead Sciences comprises about 4.5% of F&V Capital Management LLC’s investment portfolio, making the stock its 5th largest holding. F&V Capital Management LLC’s holdings in Gilead Sciences were worth $17,171,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. Quintet Private Bank Europe S.A. increased its holdings in shares of Gilead Sciences by 58.5% in the 1st quarter. Quintet Private Bank Europe S.A. now owns 2,709 shares of the biopharmaceutical company’s stock valued at $304,000 after acquiring an additional 1,000 shares during the period. RMR Wealth Builders increased its holdings in shares of Gilead Sciences by 20.4% in the 1st quarter. RMR Wealth Builders now owns 12,490 shares of the biopharmaceutical company’s stock valued at $1,400,000 after acquiring an additional 2,117 shares during the period. NorthCrest Asset Manangement LLC increased its holdings in shares of Gilead Sciences by 1.2% in the 1st quarter. NorthCrest Asset Manangement LLC now owns 117,039 shares of the biopharmaceutical company’s stock valued at $13,114,000 after acquiring an additional 1,366 shares during the period. Legacy Trust purchased a new position in shares of Gilead Sciences in the 1st quarter valued at $215,000. Finally, Ferguson Wellman Capital Management Inc. increased its holdings in shares of Gilead Sciences by 218.9% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 13,201 shares of the biopharmaceutical company’s stock valued at $1,479,000 after acquiring an additional 9,061 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GILD. Bank of America lifted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Stock Up 2.5%

Gilead Sciences stock opened at $112.05 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business’s 50-day simple moving average is $105.54 and its two-hundred day simple moving average is $102.06. The company has a market cap of $139.38 billion, a PE ratio of 302.84, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) earnings per share. The company’s revenue was down .3% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is 66.53%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares in the company, valued at approximately $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares in the company, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock worth $4,630,310 over the last quarter. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.